Spots Global Cancer Trial Database for Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Official Title: Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Study ID: NCT01650376
Study Description
Brief Summary: The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States
Swedish Cancer Institute Issaquah Campus, Issaquah, Washington, United States
Pacific Gynecology Specialists, Seattle, Washington, United States
Swedish Medical Center Cancer Institute, Seattle, Washington, United States
Swedish Cancer Institute Ballard Campus, Seattle, Washington, United States
Contact Details
Name: Saul Rivkin, MD
Affiliation: Swedish Medical Center Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
